Programme

Click on each session and speaker for further details

Each session aims to address a key problem in the breast cancer research field from both a clinical and research perspective through expert speakers, discussion and debate.

Day 1
15 Jan 2018
Day 2
16 Jan 2018

Session 1: Highlights of 2017

Basic:               Professor Clare Isacke

Translational:   Professor Peter Schmid

Early Disease:  Professor Michael Gnant

Late Disease:   Dr Mark Verrill

Chairs: Dr Daniel Hayes & Professor Arnie Purushotham

Professor Clare Isacke
Professor Clare Isacke
Professor Peter Schmid
Professor Peter Schmid
Dr. Michael Gnant
Professor Michael Gnant
Dr. Daniel Hayes
Dr Daniel Hayes
Arnie Purushotham
Professor Arnie Purushotham

Key Note Lecture, sponsored by LeCure: Dr Marc Lippman

Breast Cancer Research: Past and Future

Chaired by Professor Ian Smith

Dr Marc Lippman
Dr Marc Lippman
Professor Ian Smith

Session 2: Metastatic Disease

Managing ER+ disease:                 
Professor Stephen Johnston

Predicting outcome in metastatic breast cancer: 
Dr Aleix Prat

Evolution of resistance:
Professor Adrian Harris

Chairs: Professor Andrew Tutt & Dr Catherine Harper-Wynne

Professor Stephen Johnston
Professor Stephen Johnston
Dr. Aleix Prat
Dr Aleix Prat
Professor Adrian Harris
Professor Adrian Harris
Professor Andrew Tutt
Dr Catherine Harper-Wynne

Parallel Session 1: Ductal Carcinoma In Situ

How should we address overdiagnosis and overtreatment of DCIS?

Dr Laura Esserman

How wide a margin do we need for DCIS?

Professor Sarah Pinder

Should radiotherapy be routinely recommended after wide local excision of DCIS?

Professor David Dodwell

Abstract presentation

Chairs: Dr Tony Maxwell & Mr Mark Sibbering

Dr. Laura Esserman
Dr Laura Esserman
Professor Sarah Pinder
Professor Sarah Pinder
Professor David Dodwell
Professor David Dodwell
Mark Sibbering
Mr Mark Sibbering
Dr. Tony Maxwell
Dr Tony Maxwell

Parallel Session 2: Model systems

PDX models:                                                            
Dr Rob Clarke

Organoid models:                                                    
Dr Mathew Garnett

3D in vitro modelling using material from Breast Cancer Now Tissue Bank: 
Dr Richard Grose

Chairs: Professor Ingunn Holen & Professor Valerie Speirs

Dr. Rob Clarke
Dr Rob Clarke
Dr. Mathew Garnett
Dr Mathew Garnett
Dr Richard Grose
Dr Richard Grose
Professor Ingunn Holen
Professor Ingunn Holen
Professor Valerie Speirs
Professor Valerie Speirs

Key Note Lecture: Dr Laura Esserman

Innovation in neoadjuvant chemotherapy

Chair: Miss Julie Doughty

Dr. Laura Esserman
Dr Laura Esserman

Session 3: Neoadjuvant Therapy

Neoadjuvant therapy as a surgical tool:                                  
Professor Mike Dixon

Treatment of the axilla post neoadjuvant chemotherapy:               
Dr Judy Boughey

Neera Patel Lecture
RCB vs pCR as an end-point:                       
Dr Fraser Symmans

Latest data on imaging end points for neoadjuvant therapy:  
Dr Sarah Vinnicombe

Chairs: Dr Andreas Makris & Professor Ian Smith

Professor Mike Dixon
Professor Mike Dixon
Dr Judy Boughey
Dr. Fraser Symmans
Dr Fraser Symmans
Dr. Sarah Vinniecombe
Dr Sarah Vinnicombe
Dr. Andreas Makris
Dr Andreas Makris
Professor Ian Smith

Parallel Session 3: Workshop – A practical guide to shared decision making: Putting research into practice

The benefits of shared decision making
Professor Diana Harcourt
What can help to help make a good decision in a difficult situation like breast cancer?
Dr Alex Clarke
Tools available to support shared decision making
Dr Nicole Paraskeva

Chairs: Professor Deborah Fenlon & Lesley Turner

Professor Diana Harcourt
Dr Alex Clarke
Dr Nicole Paraskeva
Professor Deborah Fenlon

Parallel Session 4: Image analysis for scientists and pathologists

Imaging-based analysis of ErbB/HER signaling dimer and immunoregulatory molecules – from preclinical science to biomarker discovery
Professor Tony Ng
Image analysis for capturing stromal epithelial interaction
Dr Yinyin Yuan
Using digital pathology in translational breast cancer research
Professor Valerie Speirs

Chairs: Professor Tony Ng & Professor Sarah Pinder

Professor Tony Ng
Professor Tony Ng
Dr. Yinyin Yuan
Dr Yinyin Yuan
Professor Valerie Speirs
Professor Valerie Speirs
Professor Sarah Pinder
Professor Sarah Pinder

Session 4: Abstract Session

Chairs: Professor Ingunn Holen & Mr Mark Sibbering

Professor Ingunn Holen
Professor Ingunn Holen
Mark Sibbering
Mr Mark Sibbering

Parallel Session 5: Novel Clinical Trial End-points

Why do we need better trial end-points?
Professor Judith Bliss
Novel trial endpoints: Opportunities and challenges for new surrogate endpoints
Dr Marc Buyse

Chairs: Professor Judith Bliss & Dr Nicholas Turner

Judith Bliss
Professor Judith Bliss
Dr. Marc Buyse
Dr Marc Buyse
Dr Nicholas Turner

Parallel Session 6: Costs of treatment

From price to value: Keeping breast cancer care affordable
Professor Richard Sullivan
Critically examining the true value of our therapies: The only way to meaningful gains in breast cancer
Professor Tito Fojo

Chairs: Professor Arnie Purushotham & Mrs Ursula van Mann

Professor Richard Sullivan, Kings College London
Professor Richard Sullivan
Arnie Purushotham
Professor Arnie Purushotham
Ursula Van Mann

Key Note Lecture: Professor Sir David Spiegelhalter

Understanding Risk

Chair: Professor Dame Lesley Fallowfield

Professor Sir David Spiegelhalter
Professor Sir David Spiegelhalter
Professor Dame Lesley Fallowfield

Key Note Lecture, sponsored by BACR: Professor Jack Cuzick

Breast Cancer Prevention for the Population at Large

Chair: Professor Gareth Evans

Professor Jack Cuzick
Professor Jack Cuzick
Professor Gareth Evans

Session 1: Measuring and managing breast cancer risk

Stratification to Screening:                               
Professor Fiona Gilbert

Risk prediction for risk reduction:                     
Professor Gareth Evans

Findings from the Generations study:              
Professor Tony Swerdlow

Identifying genetic risk in the prevalent breast cancer population
Professor Nazneen Rahman

Chair: Dr Tony Maxwell

Professor Fiona Gilbert
Professor Fiona Gilbert
Professor Nazneen Rahman
Professor Nazneen Rahman
Tony Swerdlow
Professor Tony Swerdlow
Professor Gareth Evans
Dr. Tony Maxwell
Dr Tony Maxwell

Parallel session 1: Triple Negative Breast Cancer

Biology of the new targets:  
Professor Andrew Tutt

Complexities of TNTs:         
Dr Chuck Perou

Immunologic advances:       
Dr Giuseppe Curigliano

Chairs: Professor Ian Ellis & Professor Andrew Tutt

Professor Ian Ellis
Professor Andrew Tutt

Parallel session 2: Breast cancer heterogeneity and evolution

Genetic aspects:  
Dr Lucy Yates

Experimental modelling of heterogeneity:
Dr Rachael Natrajan

Relevance to the histopathologist:
Dr Fraser Symmans

Chairs: Professor Stephen Johnston & Professor Carlos Caldas

Professor Stephen Johnston
Professor Stephen Johnston
Professor Carlos Caldas
Professor Carlos Caldas
Dr. Lucy Yates
Dr Lucy Yates
Dr. Rachel Natrajan
Dr Rachael Natrajan
Dr. Fraser Symmans
Dr Fraser Symmans

Session 2: New treatments and measuring their impact

CDK4/6i:          
Dr Nicholas Turner

New Selective Oestrogen Receptor Downregulators   
Dr Lesley-Ann Martin

Liquid biopsies:
Professor Jacqui Shaw

Chairs: Dr Julia Gee & Professor Adrian Harris

Dr Julia Gee
Dr Julia Gee
Professor Jacqui Shaw
Dr Nicholas Turner
Professor Adrian Harris
Professor Adrian Harris

Parallel session 3: Lobular breast cancer

Biologic aspects:
Dr Steffi Oesterreich

Genetic aspects:
Professor Elinor Sawyer

Histologic dilemmas
Professor Ian Ellis

Should lobular phenotype be considered when deciding treatment?
Professor Michael Kerin

Chairs: Professor David Dodwell & Dr Adrienne Morgan

Dr. Steffi Oesterreich
Dr Steffi Oesterreich
Professor Elinor Sawyer
Professor Michael Kerin
Professor Michael Kerin
Professor Ian Ellis
Dr Adrienne Morgan
Professor David Dodwell
Professor David Dodwell

Parallel session 4: Communicating risk in the context of genomic testing

Professor Sir David Spiegelhalter &
Professor Dame Lesley Fallowfield

Professor Sir David Spiegelhalter
Professor Sir David Spiegelhalter
Professor Dame Lesley Fallowfield

Key Note Cridlan Lecture: Chuck Perou

Completion of the Cancer Genome Atlas

Chair: Dr Gill Ross

Session 3: Biomarkers and prognostic profiling

Lessons from molecular subtyping:
Professor Carlos Caldas

Clinical utility of molecular profiles:
Professor Rob Stein

Identifying who needs extended adjuvant ET:
Dr Daniel Hayes

Mutation-directed therapy:
Professor Fabrice Andre

Chairs: Professor Mitch Dowsett & Dr Fraser Symmans

Professor Mitch Dowsett
Professor Mitch Dowsett
Dr. Fraser Symmans
Dr Fraser Symmans
Professor Carlos Caldas
Professor Carlos Caldas
Professor Rob Stein
Professor Rob Stein
Dr. Daniel Hayes
Dr Daniel Hayes
Professor Fabrice Andre
Professor Fabrice Andre

Parallel session 5: Challenges of local management

Management and follow up of patients presenting with breast cancer in axillary lymph nodes and occult breast primary:
Dr Andreas Makris

When is local surgery indicated in metastatic breast cancer:
Miss Nicola Roche

What is the impact of Magnetic Resonance Imaging (MRI) scanning on breast cancer treatment?
Professor Ulrich Bick

Current and future indications for partial breast radiotherapy:
Dr Charlotte Coles

Chairs: Miss Julie Doughty & Dr Catherine Harper-Wynne

Miss Nicola Roche
Miss Nicola Roche
Professor Ulrich Bick
Professor Ulrich Bick
Dr. Andreas Makris
Dr Andreas Makris
Dr. Charlotte Coles
Dr Charlotte Coles
Dr Catherine Harper-Wynne

Parallel session 6: Clinical Trials Roadshow

Chaired by Professor Daniel Rea and Professor Judith Bliss

Judith Bliss
Professor Judith Bliss

Key Note Lecture: Professor David Cameron

Achievements of breast cancer research in the UK

Chair: Baroness Delyth Morgan

Professor David Cameron
Professor David Cameron